Tenax Therapeutics, Inc. (TENX) shareholders
Close on Nov 17, 2026Market cap $53.14MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ADAR1 Capital Management, LLC Joint filing with Daniel Schneeberger (14.00%) | 5,257,389 | 14.00% | 13G (passive) | Aug 31, 2026 |
| FMR LLC Joint filing with Abigail P. Johnson (14.90%) | 3,942,373 | 14.90% | 13G (passive) | Jun 30, 2026 |
| Vivo Opportunity Fund Holdings, L.P. Joint filing with Vivo Opportunity, LLC (9.00%) | 3,458,327 | 9.00% | 13G (passive) amendment | Jun 30, 2026 |
| Bvf Partners L P/Il Joint filing with Bvf Inc/Il (9.99%), Lampert Mark N (9.99%) and 3 more | 3,110,363 | 9.99% | 13G (passive) amendment | Jun 30, 2026 |
| Roderick Wong Joint filing with RTW Investments, LP (9.90%) | 2,866,654 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
| BlackRock, Inc. | 2,804,788 | 7.50% | 13G (passive) amendment | Sep 30, 2026 |
| Sphera Global Healthcare GP Ltd. Joint filing with Sphera Funds Management Ltd. (7.09%), Sphera Global Healthcare Management LP (7.09%) | 2,663,296 | 7.09% | 13G (passive) amendment | Sep 30, 2026 |
| ING Capital Markets LLC Joint filing with ING Groep N.V. (7.05%) | 2,639,666 | 7.05% | 13G (passive) | Aug 19, 2026 |
| Ryan Wilder Joint filing with Vestal Point Capital, LP (9.90%) | 2,470,096 | 9.90% | 13G (passive) | Sep 30, 2024 |
| Kevin Pyun Joint filing with Dellora Investments LP (6.40%), Dellora Investments Master Fund LP (5.50%) | 2,400,000 | 6.40% | 13G (passive) amendment | Oct 2, 2026 |
| Bong Y. Koh Joint filing with Nimish Shah (9.90%), VHCP Co-Investment Holdings III, LLC (9.90%) and 4 more | 1,955,105 | 9.90% | 13G (passive) amendment | Mar 31, 2026 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (6.81%), Phillip Gross (6.81%) | 1,899,495 | 6.81% | 13G (passive) amendment | Jun 30, 2026 |
| Joseph Edelman Joint filing with Perceptive Advisors LLC (5.50%), Perceptive Life Sciences Master Fund, Ltd. (5.50%) | 1,447,782 | 5.50% | 13G (passive) amendment | Mar 31, 2026 |
| Millennium Group Management LLC Joint filing with Israel A. Englander (5.10%), Millennium Management LLC (5.10%) | 1,347,130 | 5.10% | 13G (passive) | May 18, 2026 |
| Ikarian Capital, LLC Joint filing with Neil Shahrestani (6.70%) | 1,145,100 | 6.70% | 13G (passive) amendment | Mar 31, 2026 |
| VHCP Management III, LLC Joint filing with Bong Y. Koh (9.90%), Nimish Shah (9.90%) and 4 more | 692,959 | 9.90% | 13G (passive) amendment | Dec 31, 2025 |
| Janus Henderson Group PLC | 623,733 | 9.99% | 13G (passive) | Nov 28, 2025 |
| Easton Jeff Joint filing with Lind Global Fund II LP (6.62%), Lind Global Partners II LLC (6.62%) | 442,480 | 6.62% | 13G (passive) amendment | Dec 31, 2025 |
| Point72 Asset Management, L.P. Joint filing with Point72 Capital Advisors, Inc. (6.80%), Steven A. Cohen (6.80%) | 423,415 | 6.80% | 13G (passive) amendment | Dec 31, 2025 |
| RTW Investments, LP Joint filing with Roderick Wong, M.D. (9.99%) | 418,440 | 9.99% | 13G (passive) | Mar 31, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TENX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 3,942,373 | 10.53% | $57.36M | +3,619,773 | 0.00% |
| Vivo Capital, LLC | 2,500,000 | 6.68% | $36.38M | +2,291,667 | 3.32% |
| BlackRock, Inc. | 1,727,988 | 4.62% | $25.14M | +1,711,011 | 0.00% |
| Perceptive Advisors LLC | 1,700,000 | 4.54% | $24.74M | +252,218 | 0.37% |
| Vanguard Capital Management LLC | 1,147,121 | 3.07% | $16.69M | +883,700 | 0.00% |
| Millennium Management LLC | 876,230 | 2.34% | $12.75M | +342,341 | 0.00% |
| Ikarian Capital, LLC | 787,600 | 2.10% | $11.46M | −230,000 | 1.23% |
| Candriam S.C.A. | 749,588 | 2.00% | $10.90M | New | 0.05% |
| Citadel Advisors LLC | 728,561 | 1.95% | $10.60M | +576,045 | 0.00% |
| Rtw Investments, LP | 696,570 | 1.86% | $10.14M | +326,324 | 0.09% |
| Stonepine Capital Management, LLC | 660,000 | 1.76% | $9.60M | −315,200 | 5.42% |
| Geode Capital Management, LLC | 639,537 | 1.71% | $9.31M | +570,377 | 0.00% |
| Price T Rowe Associates Inc /Md/ | 607,660 | 1.62% | $8.84M | −2,343,456 | 0.00% |
| Marshall Wace, Llp | 585,578 | 1.56% | $8.52M | +233,006 | 0.01% |
| Braidwell LP | 584,412 | 1.56% | $8.50M | New | 0.31% |
| Point72 Asset Management, L.P. | 556,761 | 1.49% | $8.10M | +22,796 | 0.01% |
| Velan Capital Investment Management LP | 549,985 | 1.47% | $8.00M | −33,348 | 4.87% |
| Adage Capital Partners Gp, L.L.C. | 540,126 | 1.44% | $7.86M | – | 0.01% |
| Woodline Partners LP | 531,254 | 1.42% | $7.73M | +207,343 | 0.02% |
| State Street Corp | 510,814 | 1.36% | $7.43M | +481,824 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 111 | 30M | 81.1% | 45 / 39 | 14 / 13 | 19M | 8M |
| Q1 2026 | 80 | 22M | 57.9% | 34 / 26 | 6 / 1 | 15M | 0M |
| Q4 2025 | 49 | 7M | 18.9% | 20 / 12 | 3 / 5 | 3M | 0M |
| Q3 2025 | 34 | 5M | 12.6% | 11 / 9 | 2 / 3 | 3M | 0M |
| Q2 2025 | 26 | 2M | 6.0% | 3 / 6 | 4 / 0 | 0M | 0M |
| Q1 2025 | 23 | 2M | 5.4% | 4 / 5 | 3 / 2 | 1M | 0M |
| Q4 2024 | 21 | 1M | 3.6% | 7 / 2 | 3 / 5 | 0M | 0M |
| Q3 2024 | 19 | 1M | 3.3% | 13 / 3 | 1 / 4 | 1M | 0M |
| Q2 2024 | 11 | 0M | 0.1% | 4 / 2 | 1 / 2 | 0M | 0M |
| Q1 2024 | 9 | 0M | 0.0% | 9 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
75 funds held TENX in Q2 2026, 59% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TENX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 852,259 | 2.28% | $12.40M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 648,782 | 1.73% | $9.44M | 0.01% | Jun 30, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 445,976 | 1.19% | $6.49M | 0.05% | Jun 30, 2026 |
| Fidelity Advisor Biotechnology Fund | 445,100 | 1.19% | $6.10M | 0.28% | Jul 31, 2026 |
| Nuveen Quant Small Cap Equity Fund | 432,200 | 1.15% | $5.92M | 0.15% | Jul 31, 2026 |
| Fidelity Small Cap Discovery Fund | 335,016 | 0.90% | $4.59M | 0.20% | Jul 31, 2026 |
| Fidelity Series Small Cap Discovery Fund | 299,100 | 0.80% | $4.10M | 0.21% | Jul 31, 2026 |
| Fidelity Series Small Cap Core Fund | 282,400 | 0.75% | $3.87M | 0.25% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 277,850 | 0.74% | $4.04M | 0.00% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 275,703 | 0.74% | $3.78M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 228,271 | 0.61% | $3.32M | 0.02% | Jun 30, 2026 |
| BNY Mellon Small/Mid Cap Growth Fund | 125,362 | 0.33% | $1.82M | 0.21% | Jun 30, 2026 |
| iShares Micro-Cap ETF | 83,907 | 0.22% | $1.22M | 0.08% | Jun 30, 2026 |
| Strategic Advisers Fidelity U.S. Total Stock Fund | 76,941 | 0.21% | $913.29K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 68,684 | 0.18% | $940.97K | 0.01% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Christopher Thomas Giordano | CEO, Director | 22,174 | 0.06% | Sep 15, 2026 |
| Stuart Rich | Chief Medical Officer, Director | 12,654 | 0.03% | Jan 13, 2026 |
| Thomas R. Staab Ii | Chief Financial Officer | 15,675 | 0.04% | Sep 15, 2026 |
| Thomas McGauley | Interim CFO | 8,000 | 0.02% | Feb 3, 2026 |
| Declan Doogan | Director | 55,274 | 0.15% | Sep 17, 2026 |
| Michael H. Davidson | Director | 2,881 | 0.01% | Jan 13, 2026 |
| Gerald T. Proehl | Director | 1,667 | 0.00% | Jan 13, 2026 |
| June Sherie Almenoff | Director | 3,986 | 0.01% | Jan 13, 2026 |
| Robyn Hunter | Director | 0 | – | Jan 13, 2026 |
| ADAR1 Capital Management, LLC | 10% owner | 7,447,000 | 19.90% | Oct 21, 2026 |
| Daniel Schneeberger | 10% owner | 5,624,151 | 15.03% | Oct 21, 2026 |
| Investments LP Dellora | – | 351,071 | 0.94% | Mar 12, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| ADAR1 Capital Management, LLC 10% owner | Oct 21, 2026 | Buy | +331,979 | $1.66 | $550.69K | 7,447,000 |
| ADAR1 Capital Management, LLC 10% owner | Oct 20, 2026 | Buy | +254,342 | $1.60 | $405.73K | 7,115,021 |
| ADAR1 Capital Management, LLC 10% owner | Oct 19, 2026 | Buy | +336,528 | $1.51 | $507.01K | 6,860,679 |
| Declan Doogan Director | Sep 16, 2026 | Buy | +53,000 | $1.92 | $101.76K | 55,274 |
| Christopher Thomas Giordano CEO, Director | Sep 15, 2026 | Buy | +4,850 | $1.82 | $8.83K | 22,174 |
| Christopher Thomas Giordano CEO, Director | Sep 11, 2026 | Buy | +6,000 | $1.88 | $11.28K | 17,324 |
| Thomas R. Staab Ii Chief Financial Officer | Sep 11, 2026 | Buy | +5,675 | $1.94 | $11.01K | 15,675 |
| ADAR1 Capital Management, LLC 10% owner | Sep 3, 2026 | Buy | +900,000 | $1.78 | $1.60M | 6,524,151 |
| Daniel Schneeberger 10% owner | Sep 2, 2026 | Buy | +187,704 | $1.80 | $337.87K | 5,624,151 |
| Daniel Schneeberger 10% owner | Sep 1, 2026 | Buy | +179,058 | $1.80 | $322.30K | 5,436,447 |
| Daniel Schneeberger 10% owner | Aug 31, 2026 | Buy | +403,571 | $1.79 | $722.39K | 5,257,389 |
| Daniel Schneeberger 10% owner | Aug 24, 2026 | Buy | +107,374 | $1.75 | $187.90K | 4,853,818 |
| Daniel Schneeberger 10% owner | Aug 21, 2026 | Buy | +716,369 | $1.77 | $1.27M | 4,746,444 |
| Daniel Schneeberger 10% owner | Aug 20, 2026 | Buy | +202,124 | $1.78 | $359.78K | 4,030,075 |
| Christopher Thomas Giordano CEO, Director | Jul 13, 2026 | Option exercise | +8,500 | $5.94 | $50.49K | 11,324 |
| Christopher Thomas Giordano CEO, Director | Jul 13, 2026 | Option exercise | +219 | $3.55 | $777 | 2,824 |
| Thomas R. Staab Ii Chief Financial Officer | May 11, 2026 | Award | +10,000 | – | – | 10,000 |
| Stuart Rich Chief Medical Officer, Director | Dec 9, 2025 | Buy | +2,500 | $10.22 | $25.55K | 5,266 |
| Stuart Rich Chief Medical Officer, Director | Dec 8, 2025 | Buy | +2,500 | $10.10 | $25.25K | 5,000 |
| Stuart Rich Chief Medical Officer, Director | Dec 4, 2025 | Buy | +2,500 | $9.20 | $23.00K | 2,500 |
| Stuart Rich Chief Medical Officer, Director | Dec 3, 2025 | Buy | +1,500 | $9.08 | $13.62K | 2,766 |
| Stuart Rich Chief Medical Officer, Director | Dec 2, 2025 | Buy | +1,000 | $9.01 | $9.01K | 1,266 |
| Christopher Thomas Giordano CEO, Director | Nov 20, 2025 | Buy | +538 | $7.59 | $4.08K | 2,605 |
| Christopher Thomas Giordano CEO, Director | Nov 19, 2025 | Buy | +455 | $7.51 | $3.42K | 2,067 |
| Christopher Thomas Giordano CEO, Director | Nov 18, 2025 | Buy | +1,612 | $7.75 | $12.49K | 1,612 |
| June Sherie Almenoff Director | Nov 18, 2025 | Buy | +1,900 | $7.52 | $14.29K | 1,993 |
| June Sherie Almenoff Director | Nov 18, 2025 | Buy | +1,900 | $7.52 | $14.29K | 1,993 |
| June Sherie Almenoff Director | Nov 17, 2025 | Buy | +93 | $7.15 | $665 | 93 |
| June Sherie Almenoff Director | Nov 17, 2025 | Buy | +93 | $7.15 | $665 | 93 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +2,000 | $7.34 | $14.68K | 2,000 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +1,000 | $7.35 | $7.35K | 1,000 |
| Thomas McGauley Interim CFO | Nov 17, 2025 | Buy | +5,000 | $7.23 | $36.15K | 5,000 |
| Gerald T. Proehl Director | Aug 8, 2024 | Buy | +1,666 | – | – | 1,667 |
| Michael H. Davidson Director | Aug 8, 2024 | Buy | +2,500 | – | – | 2,881 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Sep 21, 2022 | Gift | +1,909,585 | – | – | 1,909,585 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Sep 21, 2022 | Gift | −1,909,585 | – | – | 424,347 |
| Declan Doogan Director, 10% owner | Aug 11, 2022 | Gift | −567,871 | – | – | 0 |
| Declan Doogan Director, 10% owner | Aug 11, 2022 | Gift | +567,871 | – | – | 3,637,871 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Nov 29, 2021 | Gift | −1,909,585 | – | – | 0 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Nov 29, 2021 | Gift | +1,909,585 | – | – | 1,909,585 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Oct 12, 2021 | Gift | −1,909,585 | – | – | 2,333,932 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Oct 12, 2021 | Gift | +1,909,585 | – | – | 1,909,585 |
| Declan Doogan Director, 10% owner | Jun 30, 2021 | Gift | −567,871 | – | – | 2,502,129 |
| Stuart Rich Chief Medical Officer, Director, 10% owner | Jun 11, 2021 | Option exercise | +3,581,000 | – | – | 4,243,517 |
| Michael H. Davidson Director | Jun 11, 2021 | Award | +512,000 | – | – | 606,645 |
| Declan Doogan Director, 10% owner | Jun 11, 2021 | Option exercise | +3,070,000 | – | – | 3,637,871 |
| Stuart Rich Chief Medical Officer | Jan 15, 2021 | Award | +3,581 | – | – | 3,581 |
| Stuart Rich Chief Medical Officer | Jan 15, 2021 | Award | +662,517 | – | – | 662,517 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 8, 2020 | Buy | +8,543 | $1.46 | $12.47K | 2,019,995 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 8, 2020 | Buy | +0 | – | – | 2,019,995 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 4, 2020 | Buy | +0 | – | – | 2,011,452 |
| Capital Master Fund Ltd. Armistice Director, 10% owner | Sep 4, 2020 | Buy | +23,457 | $1.41 | $33.07K | 2,011,452 |
| Armistice Capital, Llc Director, 10% owner | Sep 3, 2020 | Buy | +0 | – | – | 1,987,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 3, 2020 | Buy | +36,000 | $1.39 | $50.04K | 1,987,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 2, 2020 | Buy | +20,000 | $1.47 | $29.40K | 1,951,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 2, 2020 | Buy | +0 | – | – | 1,951,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 1, 2020 | Buy | +0 | – | – | 1,931,995 |
| Armistice Capital, Llc Director, 10% owner | Sep 1, 2020 | Buy | +30,000 | $1.46 | $43.80K | 1,931,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 31, 2020 | Buy | +20,000 | $1.45 | $29.00K | 1,901,995 |
| Armistice Capital, Llc Director, 10% owner | Aug 31, 2020 | Buy | +0 | – | – | 1,901,995 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Tenax Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 466,064 shares on Sep 2, 2026 over the last 90 days.
See a number that looks wrong?